Toxic epidermal necrolysis (TEN) is a relatively rare disease, characterized by generalized erythema, bulla formation, and exfoliation of the epidermis that resembles scalding. It is usually drug-induced and mediated by immune reactions of several types. TEN has to be differentiated from erythema multiforme and Stevens-Johnson syndrome. TEN bears a life-threatening potential and a risk for significant complications such as dehydration; secondary infections; pulmonary, gastrointestinal, and renal involvement; and late scarring with cosmetic and functional implications. Therapeutic interventions include admission in a burn center unit, systemic antibiotics and corticosteroids, topical therapy with antibacterial agents and biological dressings, and supportive measures.
References
1.
1. Hamilton ES, Greiger CW, Roth JH. Luminal poisoning with conjunctival residue. Ill Med J. 1926;49:344-344.
2.
2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br JDermatol. 1956;68:355-355.
3.
3. Lang R, Walker J. An unusual bullous eruption. S Afr Med j1956;30:97-97.
5. Millikan LE. Drug eruptions. In: Moschella S, Hurley H, eds. Dermatology, 3rd ed.Philadelphia: W.B. Saunders Company; 1992:587-587.
6.
6. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol. 1985;13:623-635.
7.
7. Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dematol. 1987;123:1171-1173.
8.
8. Chan HL, Stern RS, Arndt KA. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126: 43-47.
9.
9. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis. Incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990; 126:37-42.
10.
10. Roujeau JC, Dubertret L, Moritz S, et al. Involvement of macrophages in the pathology of toxic epidermal necrolysis. Br JDermatol. 1985;1 13:425-430.
11.
11. Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol. 1994;130:627-629.
12.
12. Yarbrough DR. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehab. 1996; 17:30-33.
13.
13. Bagot M, Charue D, Heslan M, et al. Impaired antigen presentation in toxic epidermal necrolysis. Arch Dermatol. 1993;129:721-727.
14.
14. Roujeau JC, Albengres E, Moritz S, et al. Lymphocyte transformation test in drug-induced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol. 1985;78:22-24.
15.
15. Paquet P, Pierard GE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am JDermopathol. 1997;19:127-132.
16.
16. Akosa AB, Elhag AM. Toxic epidermal necrolysis. A study of sweat glands. J Cutan Pathol. 1995;22:359-364.
17.
17. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23:1237-1244.
18.
18. Dasgupta A, O'alley J, Mallya R, Williams JG. Bronchial obstruction due to respiratory sloughing in toxic epidermal necrolysis. Otorynolaryngology. 1994;11 (3Ptl):236-242.
19.
19. Blum L, Chosidow O, Rostoker G, et al. Renal involvement in toxic epidermal necrolysis. J Am Acad Dermatol. 1996;34:1088-1090.
20.
20. Goens JSong M, Fondu P, et al. Hematological disturbances and immune mechanisms in toxic epidermal necrolysis. Br JDermatol. 1986;114:255-259.
21.
21. Parsonsj M. Management of toxic epidermal necrolysis. Cutis. 1985;36:305-307, 310-311.
22.
22. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plastic Reconstruct Surg. 1998;102:1018-1022.
23.
23. Engelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehab. 1997;18:520-524.
24.
24. Kelemen Mj, Cioffi WG, McManus WF, et al. Burn center for patients with toxic epidermal necrolysis. J Am Coll Surg. 1995;180:340-342.
25.
25. Ward DJ, Krzeminska EC, Tanner NS. Treatment of toxic epidermal necrolysis and a review of six cases. Burns. 1990;16:97-104.
26.
26. Prendiville JS, Hebert AA. Management of Stevens-Johnson sydrome and toxic epidermal necrolysis in children. J Pediatr.1989;115:881-887.
27.
27. Sowder LL. Biobrane wound dressing used in treatment of toxic epidermal necrolysis: a case report. J Burn Care Rehab. 1990;11:237-239.
28.
28. Birchall N, Langdon R, Cuono C, McGuire J. Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin. JAm Acad Dematol. 1987;16(2 Ptl):368-372.
29.
29. Pasricha JS, Khaitan BK, Shantharam R, et al. Toxic epidermal necrolysis. Int JDermatol. 1996;35:523-527.
30.
30. Hummell RP. Care of the burn wound. In: Hummel RP, ed. Clinical Burn Therapy, A Management and Prevention Guide. Boston: PSG; 1982:85-85.
31.
31. Jones WG, Halebian PMadden M, et al. Drug-induced toxic epidermal necrolysis in children. J Pediatr Surg. 1989;24:167-170.
32.
32. Sakellariou G, Koukoudis P, Karponzas J, et al. Plasma exchange treatment in druginduced toxic epidermal necrolysis. Int J Artif Organs. 1991;14:634-638.
33.
33. Chaidemenos GC, Chrysomallis F, Sambolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36:218-221.
34.
34. Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40:458-461.
35.
35. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.
36.
36. Goulden V, Goodfield MJ. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br JDermatol. 1996; 135:305-306.
37.
37. Ruocco V, Bimonte D, Luongo C, Florio M. Hyperbaric oxygen treatment of toxic epidermal necrolysis. Cutis. 1986;38:267-271.
38.
38. Coss-Bu JA, Jefferson LS, Levy ML, et al. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract. 1999; 12:81-84.
